Previous 10 | Next 10 |
Esperion Therapeutics ( ESPR ) Q4 results : Revenues: $1M. More news on: Esperion Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Esperion Therapeutics (NASDAQ: ESPR ): Q4 GAAP EPS of -$2.26 beats by $0.49 . More news on: Esperion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31, 2019. “2019 was a precedent setting year for our Lipid Management Team highlighted ...
- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins - - First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved - - Esperion’s Second Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved...
Kindness is the language which the deaf can hear and the blind can see ." - Mark Twain Esperion Therapeutics ( ESPR ) sold off nearly 10% on Friday despite garnering FDA approval for Nexletol (bempedoic acid) as an adjunct to diet for lowering LDL-C ("bad" cholesterol) in adults w...
Esperion Gets FDA Nod for Nexletol Esperion Therapeutics (ESPR) reported that its lead drug candidate Nexletol has been approved by the FDA for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. The treatment has ...
The U.S. Food and Drug Administration announced on Friday afternoon that it had officially approved a new cholesterol-lowering drug developed by Esperion Therapeutics (NASDAQ: ESPR) . Nexletol (also known as bempedoic acid) is intended to be used as an add-on treatment for patients already ta...
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients – – NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism – – Fills an Unmet Need ...
The FDA approves Esperion Therapeutics' ( ESPR -8.7% ) Nexletol (bempedoic acid) as an adjunct to diet for lowering LDL-C ("bad" cholesterol) in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. More news on: Esperion T...
Esperion Therapeutics Anticipates Positive News For Two Of Its Drug Candidates Esperion Therapeutics ( ESPR ) is on the verge of a major catalyst as the company awaits the FDA decision for bempedoic acid as a treatment for increased LDL cholesterol. The agency is scheduled to deliver its...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...